Brought to you by 
Bayer licenses Natrecor from Scios for $60mm
28 Oct 1999
Executive Summary
Bayer has licensed worldwide rights to Scios's congestive heart failure (CHF) drug Natrecor (nesiritide). Bayer will pay (uf)$20mm cash upfront, up to an additional $40mm upon US, European, and Japanese regulatory milestones, plus sales royalties.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Terminated
Deal Type
-
Alliance
- Co-Promotion
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com